Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes

Adv Nutr. 2021 Jul 30;12(4):1074-1086. doi: 10.1093/advances/nmab031.

Abstract

More than a year has passed since the first reported case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection in the city of Wuhan in China's Hubei Province. Until now, few antiviral medications (e.g., remdesivir) or drugs that target inflammatory complications associated with SARS-CoV2 infection have been considered safe by public health authorities. By the end of November 2020, this crisis had led to >1 million deaths and revealed the high susceptibility of people with pre-existing comorbidities (e.g., obesity, diabetes, coronary heart disease, hypertension) to suffer from a severe form of the disease. Elderly people have also been found to be highly susceptible to SARS-CoV2 infection and morbidity. Gastrointestinal manifestations and gut microbial alterations observed in SARS-CoV2-infected hospitalized patients have raised awareness of the potential role of intestinal mechanisms in increasing the severity of the disease. It is therefore critically important to find alternative or complementary approaches, not only to prevent or treat the disease, but also to reduce its growing societal and economic burden. In this review, we explore potential nutritional strategies that implicate the use of polyphenols, probiotics, vitamin D, and ω-3 fatty acids with a focus on the gut microbiome, and that could lead to concrete recommendations that are easily applicable to both vulnerable people with pre-existing metabolic comorbidities and the elderly, but also to the general population.

Keywords: COVID-19; gut microbiota; nutrition; obesity; omega-3; polyphenols; probiotics; vitamin D.

Publication types

  • Review

MeSH terms

  • Aged
  • COVID-19*
  • Gastrointestinal Microbiome*
  • Humans
  • Probiotics*
  • RNA, Viral
  • SARS-CoV-2

Substances

  • RNA, Viral